276 related articles for article (PubMed ID: 34795058)
41. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
[TBL] [Abstract][Full Text] [Related]
42. Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.
Suda K; Rozeboom L; Furugaki K; Yu H; Melnick MAC; Ellison K; Rivard CJ; Politi K; Mitsudomi T; Hirsch FR
Biomed Res Int; 2017; 2017():7694202. PubMed ID: 29119113
[TBL] [Abstract][Full Text] [Related]
43. Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis.
Liu P; Cong X; Liao S; Jia X; Wang X; Dai W; Zhai L; Zhao L; Ji J; Ni D; Liu Z; Chen Y; Pan L; Liu W; Zhang J; Huang M; Liu B; Tan M
Cell Death Differ; 2022 Jan; 29(1):1-13. PubMed ID: 34215846
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients.
Kumar S; Pandey M; Mir IA; Mukhopadhyay A; Sharawat SK; Jain D; Saikia J; Malik PS; Kumar S; Mohan A
Hum Cell; 2022 Jan; 35(1):286-298. PubMed ID: 34786661
[TBL] [Abstract][Full Text] [Related]
45. Targeting FBXO22 enhances radiosensitivity in non-small cell lung cancer by inhibiting the FOXM1/Rad51 axis.
Chen Y; Zhou Y; Feng X; Wu Z; Yang Y; Rao X; Zhou R; Meng R; Dong X; Xu S; Zhang S; Wu G; Jie X
Cell Death Dis; 2024 Jan; 15(1):104. PubMed ID: 38296976
[TBL] [Abstract][Full Text] [Related]
46. HYR-2 plays an anti-lung cancer role by regulating PD-L1 and Akkermansia muciniphila.
Teng L; Wang K; Chen W; Wang YS; Bi L
Pharmacol Res; 2020 Oct; 160():105086. PubMed ID: 32687951
[TBL] [Abstract][Full Text] [Related]
47. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
48. [Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer].
Zhi X; Li W; Wang S; Wang J
Zhongguo Fei Ai Za Zhi; 2019 Dec; 22(12):779-785. PubMed ID: 31874674
[TBL] [Abstract][Full Text] [Related]
49. CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma.
Zhang R; Wang J; Du Y; Yu Z; Wang Y; Jiang Y; Wu Y; Le T; Li Z; Zhang G; Lv L; Ma H
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007240
[TBL] [Abstract][Full Text] [Related]
50. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
51. The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis.
Chen XJ; Yuan SQ; Duan JL; Chen YM; Chen S; Wang Y; Li YF
Dis Markers; 2020; 2020():6717912. PubMed ID: 33488843
[TBL] [Abstract][Full Text] [Related]
52. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
53. Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC.
Jiang L; Guo F; Liu X; Li X; Qin Q; Shu P; Li Y; Wang Y
Sci Rep; 2019 Mar; 9(1):3705. PubMed ID: 30842489
[TBL] [Abstract][Full Text] [Related]
54. FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2.
Ma J; Wu Y; Cheng S; Yang W; Zhong L; Li Q; Fang L
Dig Dis Sci; 2023 May; 68(5):1913-1922. PubMed ID: 36515852
[TBL] [Abstract][Full Text] [Related]
55. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
[TBL] [Abstract][Full Text] [Related]
56. A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non-Small-Cell Lung Cancer (NSCLC) Bronchoscopy Specimen.
Vannitamby A; Hendry S; Makadia T; Danks J; Slavin J; Irving L; Steinfort D; Bozinovski S
J Mol Diagn; 2019 Mar; 21(2):186-197. PubMed ID: 30772141
[TBL] [Abstract][Full Text] [Related]
57. TP53/p53-FBXO22-TFEB controls basal autophagy to govern hormesis.
Suzuki N; Johmura Y; Wang TW; Migita T; Wu W; Noguchi R; Yamaguchi K; Furukawa Y; Nakamura S; Miyoshi I; Yoshimori T; Ohta T; Nakanishi M
Autophagy; 2021 Nov; 17(11):3776-3793. PubMed ID: 33706682
[TBL] [Abstract][Full Text] [Related]
58. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
[TBL] [Abstract][Full Text] [Related]
59. Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer.
Shimizu K; Okita R; Saisho S; Maeda AI; Nojima Y; Nakata M
Anticancer Res; 2018 Aug; 38(8):4637-4644. PubMed ID: 30061230
[TBL] [Abstract][Full Text] [Related]
60. The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer.
Kim GJ; Lee JH; Park WJ; Lee HW; Hwang IS; Lee DH
Ann Clin Lab Sci; 2019 May; 49(3):317-323. PubMed ID: 31308030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
